Kymera Therapeutics Ownership
| KYMR Stock | USD 32.54 0.67 2.02% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 76.1 M | Current Value 80 M | Avarage Shares Outstanding 51.8 M | Quarterly Volatility 15.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Kymera |
Kymera Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The book value of Kymera Therapeutics was now reported as 12.88. The company has Price/Earnings To Growth (PEG) ratio of 0.64. Kymera Therapeutics recorded a loss per share of 2.98. The entity had not issued any dividends in recent years. Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodys own natural protein degradation system. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Kymera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 160 people. To find out more about Kymera Therapeutics contact the company at 857 285 5300 or learn more at https://www.kymeratx.com.Besides selling stocks to institutional investors, Kymera Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Kymera Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Kymera Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Kymera Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Kymera Therapeutics Insider Trades History
Roughly 2.0% of Kymera Therapeutics are currently held by insiders. Unlike Kymera Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Kymera Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Kymera Therapeutics' insider trades
Kymera Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kymera Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kymera Therapeutics backward and forwards among themselves. Kymera Therapeutics' institutional investor refers to the entity that pools money to purchase Kymera Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.1 M | Redmile Group, Llc | 2024-12-31 | 1.1 M | Rock Springs Capital Management Lp | 2024-12-31 | 1 M | Merck & Co Inc | 2024-12-31 | 772.2 K | Jennison Associates Llc | 2024-12-31 | 716.9 K | Deerfield Management Co | 2024-12-31 | 593 K | Woodline Partners Lp | 2024-12-31 | 537.4 K | Avidity Partners Management Lp | 2024-12-31 | 500 K | Ubs Group Ag | 2024-12-31 | 469.8 K | T. Rowe Price Associates, Inc. | 2024-12-31 | 6.9 M | Baker Bros Advisors Lp | 2024-12-31 | 6 M |
Kymera Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kymera Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kymera Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kymera Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kymera Therapeutics Outstanding Bonds
Kymera Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kymera Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kymera bonds can be classified according to their maturity, which is the date when Kymera Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Kymera Therapeutics Corporate Filings
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify | |
F4 | 13th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with Kymera Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Kymera Stock
Moving against Kymera Stock
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.